Normal P50 suppression in schizophrenia treated with atypical antipsychotic medications

American Journal of Psychiatry

Volumn 157, Issue 5, 2000, Pages 767-771

  Light, Gregory A ^a   Geyer, Mark A ^a   Clementz, Brett A ^a   Cadenhead, Kristin S ^a   Braff, David L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACOUSTIC STIMULATION; ADULT; ANTIPSYCHOTIC AGENTS; AUDITORY PERCEPTION; BENZODIAZEPINES; CLOZAPINE; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034062159     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.5.767     Document Type: Article

References (47)

1. Braff DL: Psychophysiological and information processing approaches to schizophrenia, in Neurobiological Foundation of Mental Illness. Edited by Charney DS, Nestler E, Bunney BS. New York, Oxford University Press, 1999, pp 258-271
2. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R: Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982; 17:639-654
3. Adler LE, Freedman R, Ross RG, Olincy A, Waldo MC: Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry 1999; 46:8-18
4. Boutros NN, Zouridakis G, Overall J: Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 1991; 22:40-45
5. Cardenas VA, Gerson J, Fein G: The reliability of P50 suppression as measured by the conditioning/testing ratio is vastly improved by dipole modeling. Biol Psychiatry 1993; 33:335-344
6. Clementz BA, Geyer MA, Braff DL: P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry 1997; 41:1035-1044
7. Clementz BA, Geyer MA, Braff DL: Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Res 1998; 30:71-80
8. Clementz BA, Geyer MA, Braff DL: Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry 1998; 155:1691-1694
9. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE: P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res 1998; 33: 157-167
10. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, McRae K, Cawthra E, Waldo M: Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects: human recordings, computer simulation, and an animal model. Arch Gen Psychiatry 1996; 53:1114-1121
11. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R: Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 1998; 44:98-106
12. Jin Y, Potkin SG, Patterson JV, Sandman CA, Hetrick WP, Bunney WE Jr: Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 1997; 70:71-81
13. Judd LL, McAdams L, Budnick B, Braff DL: Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992; 149:488-493
14. Nagamoto HT, Adler LE, Waldo MC, Freedman R: Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry 1989; 25:549-561
15. Ward PB, Hoffer LD, Liebert BJ, Catts SV, O'Donnell M, Adler LE: Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res 1996; 64:121-135
16. Braff DL, Geyer MA: Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 1990; 47:181-188
17. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R: Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992; 32:607-616
18. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94:587-592
19. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R: Deficits in sensory gating in schizophrenic patients and their relatives: evidence obtained with auditory evoked responses. Arch Gen Psychiatry 1984; 41:607-612
20. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE, Nagamoto HT, Wender P, Byerley W, Plaetke R, Freedman R: Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res 1991; 39:257-268
21. Waldo M, Myles-Worsley M, Madison A, Byerley W, Freedman R: Sensory gating deficits in parents of schizophrenics. Am J Med Genet 1995; 60:506-511
22. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD: Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 1983; 18:537-551
23. Franks RD, Adler LE, Waldo MC, Alpert J, Freedman R: Neurophysiological studies of sensory gating in mania: comparison with schizophrenia Biol Psychiatry 1983; 18:989-1005
24. Light GA, Malaspina DM, Geyer MA, Luber BM, Coleman EA, Sackeim HA, Braff DL: Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry 1999; 46:990-996
25. Adler LE, Rose G, Freedman R: Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine, and haloperidol. Biol Psychiatry 1986; 21:787-798
26. Adler LE, Pang K, Gerhardt G, Rose GM: Modulation of the gating of auditory evoked potentials by norepinephrine: pharmacological evidence obtained using a selective neurotoxin. Biol Psychiatry 1988; 24:179-190
27. Stevens KE, Fuller LL, Rose GM: Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res 1991; 555:91-98
28. Stevens KE, Luthman J, Lindqvist E, Johnson RG, Rose GM: Effects of neonatal dopamine depletion on sensory inhibition in the rat. Pharmacol Biochem Behav 1996; 53:817-823
29. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154:799-804
30. Arnt J, Skarsfeldt T: Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998; 18:63-101
31. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996; 40:181-188
32. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G, Hea R, Griffith J: Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4 hydroxyphenylglycol. Neuropsychobiology 1999; 39:10-17
33. Seligman MEP, Levant RF: Managed care policies rely on inadequate science. Professional Psychology: Research and Practice 1998; 29:211-212
34. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1995
35. Andreasen NC: Modified Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1984
36. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1984
37. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R: Gating of auditory response in schizophrenics and normal controls: effects of recording site and stimulation interval on the P50 wave. Schizophr Res 1991; 4:31-40
38. Jerger K, Biggins C, Fein G: P50 suppression is not affected by attentional manipulations. Biol Psychiatry 1992; 31:365-377
39. Cohen J: Statistical Power Analysis for the Behavioral Sciences. New York, Academic Press, 1977
40. Cohen J: The earth is round (p < .05). Am Psychol 1994; 49: 997-1003
41. Cohen J: Things I have learned (so far). Am Psychol 1990; 45: 1304-1312
42. McCallin K, Cardenas VA, Fein G: P50 event-related brain potential amplitude and suppression measurements recorded with subjects seated versus supine. Biol Psychiatry 1997; 41: 902-905
43. Yee CM, Nuechterlein KH, Morris SE, White PM: P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 1998; 107:691-698
44. Kumari V, Soni W, Sharma T: Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 1999; 156:1046-1051
45. Braff DL, Stone C, Callaway E, Geyer MA, Glick I, Bali L: Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978; 15:339-343
46. Braff DL, Grillon C, Geyer MA: Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49:206-215
47. Grillon C, Ameli R, Charney DS, Krystal J, Braff DL: Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 1992; 32:939-943